N Malats

Author PubWeight™ 48.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. J Epidemiol Community Health 1999 4.43
2 Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997 2.19
3 Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health 2002 2.13
4 Improving strategies for detecting genetic patterns of disease susceptibility in association studies. Stat Med 2008 1.86
5 Basic molecular genetics for epidemiologists. J Epidemiol Community Health 2003 1.62
6 Diagnostic certainty and potential for misclassification in exocrine pancreatic cancer. PANKRAS I Project Investigations. J Clin Epidemiol 1994 1.50
7 Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites. J Epidemiol Community Health 1991 1.41
8 Occurrence, trends and environment etiology of pancreatic cancer. Scand J Work Environ Health 1998 1.38
9 Occupation and bladder cancer in a hospital-based case-control study in Spain. Occup Environ Med 2007 1.32
10 Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. ISDS II Project Investigators. Eur J Cancer 1994 1.25
11 Biomarkers of exposure to polycyclic aromatic hydrocarbons from environmental air pollution. Occup Environ Med 2004 1.25
12 Assessment of lifetime exposure to trihalomethanes through different routes. Occup Environ Med 2006 1.15
13 Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 2000 1.11
14 Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 2003 1.06
15 Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda. J Epidemiol Community Health 2000 0.96
16 Learning from case reports: diagnostic issues in an epidemiologic study of pancreatic cancer. J Clin Epidemiol 1998 0.95
17 Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 2003 0.93
18 Emergency admission for cancer: a matter of survival? Br J Cancer 1998 0.93
19 Review of studies of selected metabolic polymorphisms and cancer. IARC Sci Publ 1999 0.92
20 Myelodysplastic syndromes and malignant solid tumors: analysis of 21 cases. Am J Hematol 1992 0.92
21 Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br J Cancer 2012 0.91
22 Human cancer, carcinogenic exposures and mutation spectra. Mutat Res 1999 0.89
23 Predictors of the interval between onset of symptoms and first medical visit in patients with digestive tract cancer. Int J Oncol 1996 0.88
24 Risk of pancreatic cancer and occupational exposures in Spain. PANKRAS II Study Group. Ann Occup Hyg 2000 0.87
25 Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer's judgement. Eur J Epidemiol 1996 0.87
26 [Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee and diet in cancer of the exocrine pancreas and extrahepatic biliary tract]. Gac Sanit 1996 0.87
27 DDT and pancreatic cancer. J Natl Cancer Inst 1993 0.85
28 Re: Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1994 0.84
29 Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997 0.84
30 Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group. Eur J Epidemiol 2000 0.83
31 Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut 2002 0.83
32 Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. PANKRAS II Study Group. Dig Dis Sci 1999 0.82
33 Sex as a prognostic factor in gastric cancer. Eur J Cancer 1996 0.82
34 Vegetable and fruit intake and the risk of lung cancer in women in Barcelona, Spain. Eur J Cancer 1997 0.81
35 The inherited genetic component of sporadic pancreatic adenocarcinoma. Pancreatology 2009 0.81
36 Correction: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1999 0.80
37 Work in the textile industry in Spain and bladder cancer. Occup Environ Med 2007 0.79
38 Overall evaluation and research perspectives. IARC Sci Publ 1999 0.79
39 Why study metabolic susceptibility to cancer? IARC Sci Publ 1999 0.78
40 [The symptom-diagnosis interval: a possible approximation to the natural history of neoplasms]. Rev Sanid Hig Publica (Madr) 1990 0.78
41 Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group. Int J Epidemiol 2000 0.78
42 Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. Public Health Genomics 2013 0.78
43 EU Pancreas: an integrated European platform for pancreas cancer research--from basic science to clinical and public health interventions for a rare disease. Public Health Genomics 2014 0.76
44 Decreased survival of patients with lung cancer admitted to a teaching hospital through the emergency department in Barcelona, Spain. J Epidemiol Community Health 1998 0.75
45 [Molecular epidemiology]. Med Clin (Barc) 1993 0.75
46 [Active pulmonary tuberculosis and cancer of the bronchi]. Rev Clin Esp 1990 0.75
47 Public health genomics in Spain: the status of a non-existing reality. Public Health Genomics 2012 0.75
48 [The search of risk factors for pancreatic cancer: practice, patience and paradigms]. Gastroenterol Hepatol 1997 0.75
49 Strategic issues in the design and interpretation of studies on metabolic polymorphisms and cancer. IARC Sci Publ 1999 0.75